Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucia Gozzo

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Nutrients|August 10, 2024
Flavan-3-ols and Vascular Health: Clinical Evidence and Mechanisms of ActionJustyna Godos, Giovanni Luca Romano, Samuele Laudani, et al.
Annals of Hematology|January 8, 2021
Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA)Massimo Breccia, Simone Celant, Pier Paolo Olimpieri, et al.
Frontiers in Pharmacology|April 2, 2024
Resveratrol and vascular health: evidence from clinical studies and mechanisms of actions related to its metabolites produced by gut microbiotaJustyna Godos, Giovanni Luca Romano, Lucia Gozzo, et al.
Journal of Clinical Medicine|July 29, 2025
Length of Washout Period After Remission Does Not Influence Relapse Risk in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents Combined with VenetoclaxFanny Erika Palumbo, Andrea Duminuco, Laura Longo, et al.
Pharmaceuticals (Basel, Switzerland)|February 24, 2024
Isoflavones Effects on Vascular and Endothelial Outcomes: How Is the Gut Microbiota Involved?Samuele Laudani, Justyna Godos, Giovanni Luca Romano, et al.
Journal of Clinical Medicine|August 14, 2025
Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational StudyErmelinda Longo, Fanny Erika Palumbo, Andrea Duminuco, et al.
Journal of Clinical Pharmacology|March 28, 2022
Pegylated Asparaginase-Induced Liver Injury: A Case-Based Review and Data From PharmacovigilanceCalogero Vetro, Andrea Duminuco, Lucia Gozzo, et al.
Hematology Reports|October 28, 2025
Vitamin K Antagonists (VKAs) and Novel Oral Anticoagulants (NOACs) Safety Comparison Based on Data from EudraVigilance DatabasePier Paolo Olimpieri, Fanny Erika Palumbo, Gaetano Giuffrida, et al.
European Journal of Haematology|August 14, 2025
Extramedullary Acute Myeloid Leukemia: Evaluating Azacitidine-Venetoclax Combination Outcomes and the Role of Molecular Genetics and Bone Marrow InvolvementFanny E Palumbo, Calogero Vetro, Valeria Calafiore, et al.
Frontiers in Pharmacology|December 13, 2021
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance DatabaseLucia Gozzo, Calogero Vetro, Serena Brancati, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Nutrients|August 10, 2024
Flavan-3-ols and Vascular Health: Clinical Evidence and Mechanisms of ActionJustyna Godos, Giovanni Luca Romano, Samuele Laudani, et al.
Annals of Hematology|January 8, 2021
Mortality rate in patients with chronic myeloid leukemia in chronic phase treated with frontline second generation tyrosine kinase inhibitors: a retrospective analysis by the monitoring registries of the Italian Medicines Agency (AIFA)Massimo Breccia, Simone Celant, Pier Paolo Olimpieri, et al.
Frontiers in Pharmacology|April 2, 2024
Resveratrol and vascular health: evidence from clinical studies and mechanisms of actions related to its metabolites produced by gut microbiotaJustyna Godos, Giovanni Luca Romano, Lucia Gozzo, et al.
Journal of Clinical Medicine|July 29, 2025
Length of Washout Period After Remission Does Not Influence Relapse Risk in Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents Combined with VenetoclaxFanny Erika Palumbo, Andrea Duminuco, Laura Longo, et al.
Pharmaceuticals (Basel, Switzerland)|February 24, 2024
Isoflavones Effects on Vascular and Endothelial Outcomes: How Is the Gut Microbiota Involved?Samuele Laudani, Justyna Godos, Giovanni Luca Romano, et al.
Journal of Clinical Medicine|August 14, 2025
Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational StudyErmelinda Longo, Fanny Erika Palumbo, Andrea Duminuco, et al.
Journal of Clinical Pharmacology|March 28, 2022
Pegylated Asparaginase-Induced Liver Injury: A Case-Based Review and Data From PharmacovigilanceCalogero Vetro, Andrea Duminuco, Lucia Gozzo, et al.
Hematology Reports|October 28, 2025
Vitamin K Antagonists (VKAs) and Novel Oral Anticoagulants (NOACs) Safety Comparison Based on Data from EudraVigilance DatabasePier Paolo Olimpieri, Fanny Erika Palumbo, Gaetano Giuffrida, et al.
European Journal of Haematology|August 14, 2025
Extramedullary Acute Myeloid Leukemia: Evaluating Azacitidine-Venetoclax Combination Outcomes and the Role of Molecular Genetics and Bone Marrow InvolvementFanny E Palumbo, Calogero Vetro, Valeria Calafiore, et al.
Frontiers in Pharmacology|December 13, 2021
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance DatabaseLucia Gozzo, Calogero Vetro, Serena Brancati, et al.
Pageof 5